Phase 1 results demonstrate TMB-365 antiviral activity and tolerability, supporting continued development as a differentiated antibody for combination HIV treatment Complementary laboratory susceptibility findings support the scientific rationale for the TMB-365/TMB-380 antibody-only maintenance regimen TAIPEI, Taiwan, Oct. 21, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147), a commercial-stage CD4-targeted biologics company advancing antibody-based therapies for long-acting HIV treatment, today anno ...